Abstract
Alzheimer disease (AD) and Creutzfeldt-Jakob disease (CJD) are sporadic and genetic neurodegenerative conditions characterized by brain accumulation and deposition of protein aggregates. In AD, the key pathogenic event is linked to the formation of a 4-kDa amyloid β (Aβ) peptide, generated by sequential cleavages of the amyloid precursor protein (APP). In CJD and other prion diseases, the process is initiated by conformational changes of the cellular prion protein, or PrPC, into a β-sheet rich isoform, named PrPsc, which acquires protease-resistance and detergent insolubility. Once generated, Aβ and PrPsc are highly prone to misassembly under thermodynamically favourable oligomeric forms and protofibril/fibril structures. The variety of physicochemical states exhibited by Aβ and PrPsc is accounted for by distinct molecular forms with different amino and/or carboxyl termini and alternative conformations. Unlike Aβ, PrPsc is also infectious, and this feature poses public health concerns, as in the case of iatrogenic and variant CJD (vCJD). Several lines of evidence suggest that Aβ and PrPsc are the main factors responsible for death of selected neuronal populations in brains of AD and prion diseases victims. Therefore, in addition to symptomatic treatment of dementia, therapeutic efforts are currently aimed at testing the efficacy of disease-modifying, anti-amyloid therapies. Experimental and clinical therapeutic interventions include passive and active immunization against amyloidogenic peptides, non immunological strategies, as well as drugs enhancing the nonamyloidogenic protein processing. In this review, we focus on molecular mechanisms of AD and prion diseases, and on novel treatment approaches.
Keywords: Alzheimer disease, prion diseases, transmissible spongiform encephalopathies, Creutzfeldt-Jakob disease, amyloid precursor protein, dementia, anti-amyloid therapies, protein-misfolding diseases
Current Medicinal Chemistry
Title: Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges
Volume: 13 Issue: 16
Author(s): Salvatore Monaco, Gianluigi Zanusso, Sara Mazzucco and Nicola Rizzuto
Affiliation:
Keywords: Alzheimer disease, prion diseases, transmissible spongiform encephalopathies, Creutzfeldt-Jakob disease, amyloid precursor protein, dementia, anti-amyloid therapies, protein-misfolding diseases
Abstract: Alzheimer disease (AD) and Creutzfeldt-Jakob disease (CJD) are sporadic and genetic neurodegenerative conditions characterized by brain accumulation and deposition of protein aggregates. In AD, the key pathogenic event is linked to the formation of a 4-kDa amyloid β (Aβ) peptide, generated by sequential cleavages of the amyloid precursor protein (APP). In CJD and other prion diseases, the process is initiated by conformational changes of the cellular prion protein, or PrPC, into a β-sheet rich isoform, named PrPsc, which acquires protease-resistance and detergent insolubility. Once generated, Aβ and PrPsc are highly prone to misassembly under thermodynamically favourable oligomeric forms and protofibril/fibril structures. The variety of physicochemical states exhibited by Aβ and PrPsc is accounted for by distinct molecular forms with different amino and/or carboxyl termini and alternative conformations. Unlike Aβ, PrPsc is also infectious, and this feature poses public health concerns, as in the case of iatrogenic and variant CJD (vCJD). Several lines of evidence suggest that Aβ and PrPsc are the main factors responsible for death of selected neuronal populations in brains of AD and prion diseases victims. Therefore, in addition to symptomatic treatment of dementia, therapeutic efforts are currently aimed at testing the efficacy of disease-modifying, anti-amyloid therapies. Experimental and clinical therapeutic interventions include passive and active immunization against amyloidogenic peptides, non immunological strategies, as well as drugs enhancing the nonamyloidogenic protein processing. In this review, we focus on molecular mechanisms of AD and prion diseases, and on novel treatment approaches.
Export Options
About this article
Cite this article as:
Monaco Salvatore, Zanusso Gianluigi, Mazzucco Sara and Rizzuto Nicola, Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges, Current Medicinal Chemistry 2006; 13 (16) . https://dx.doi.org/10.2174/092986706777585022
DOI https://dx.doi.org/10.2174/092986706777585022 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
DNAJ Proteins and Protein Aggregation Diseases
Current Topics in Medicinal Chemistry Medicinal Plants in Neurodegenerative Diseases: Perspective of Traditional Persian Medicine
Current Drug Metabolism Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket
Current Medicinal Chemistry Treatment of Alzheimer's Disease: Classical Therapeutic Approach
Current Pharmaceutical Analysis Principles and Applications of Diffuse Optical Imaging for the Brain
Current Medical Imaging Hallucinations Associated with Topiramate Therapy: A Case Report and Review of the Literature
Current Drug Safety Therapeutic Opportunities in Alzheimer Disease: One for all or all for One?
Current Medicinal Chemistry Nanowired Drug Delivery of Antioxidant Compound H-290/51 Enhances Neuroprotection in Hyperthermia-Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
Current Pharmaceutical Design The Applications of Pharmacogenomics to Neurological Disorders
Current Molecular Medicine Meet Our Associate Editor
Current Alzheimer Research Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson´s Disease
Current Neuropharmacology Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation
Current Drug Safety Modifiable Risk Factors Associated with Alzheimer’s Disease with Special Reference to Sleep Disturbance
CNS & Neurological Disorders - Drug Targets A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews Oxidative Stress in Post-Acute Ischemic Stroke Patients after Intensive Neurorehabilitation
Current Neurovascular Research Potential of Photobiomodulation to Induce Differentiation of Adipose- Derived Mesenchymal Stem Cells into Neural Cells
Current Stem Cell Research & Therapy Review of Theoretical Studies for Prediction of Neurodegenerative Inhibitors
Mini-Reviews in Medicinal Chemistry Sirtuins: Common Targets in Aging and in Neurodegeneration
Current Drug Targets Moderate Wine Consumption in the Prevention of Metabolic Syndrome and its Related Medical Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets